- TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
- TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
- TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
- TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
- TScan Therapeutics Announces Closing of Upsized Public Offering
- TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
- TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
- TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
- TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
- TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
More ▼
Key statistics
On Friday, TScan Therapeutics Inc (TCRX:NMQ) closed at 7.73, -14.96% below its 52-week high of 9.09, set on May 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.88 |
---|---|
High | 8.22 |
Low | 7.67 |
Bid | 7.79 |
Offer | 10.50 |
Previous close | 7.80 |
Average volume | 174.61k |
---|---|
Shares outstanding | 57.14m |
Free float | 52.44m |
P/E (TTM) | -- |
Market cap | 441.69m USD |
EPS (TTM) | -2.49 USD |
Data delayed at least 15 minutes, as of May 10 2024 21:00 BST.
More ▼